KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Assets: 2013-2025

Historic Assets for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $607.8 million.

  • Xenon Pharmaceuticals' Assets fell 27.28% to $607.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.8 million, marking a year-over-year decrease of 27.28%. This contributed to the annual value of $798.1 million for FY2024, which is 17.27% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Assets of $607.8 million as of Q3 2025, which was down 9.85% from $674.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Assets high stood at $964.8 million for Q4 2023, and its period low was $264.4 million during Q3 2021.
  • In the last 3 years, Xenon Pharmaceuticals' Assets had a median value of $743.3 million in 2025 and averaged $773.0 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Assets skyrocketed by 202.35% in 2021, and later decreased by 27.28% in 2025.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Assets stood at $572.0 million in 2021, then surged by 31.84% to $754.1 million in 2022, then grew by 27.93% to $964.8 million in 2023, then dropped by 17.27% to $798.1 million in 2024, then dropped by 27.28% to $607.8 million in 2025.
  • Its Assets stands at $607.8 million for Q3 2025, versus $674.3 million for Q2 2025 and $743.3 million for Q1 2025.